Please broadcast the following special announcement as soon as possible, and repeat it at suitable intervals:
A voltage dip occurred in New Territories and Kowloon districts at 12.28pm today (March 30), resulting in cases of person being shut in lift. The Fire Services Department has not received any further reports of lift incidents due to voltage dip.
EC Healthcare (the “Company”, which together with its subsidiaries is referred to as the “Group”, SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the excellent result in the “All-Asia Executive Team Rankings 2023” under the category of Healthcare, Pharma & Biotech organized by Institutional Investor, an international magazine. The Group is delighted recognize as The Most Honoured Company (Healthcare, Pharma & Biotech) in the division – Mid & Smallcap and Asia (excluding mainland China), which represents recognition of the Group’s impressive performance by the investors and the market.
Recognized as an authoritative ranking by industries, “All-Asia Executive Team Rankings” celebrates the outstanding companies and management teams in Asia. Buy-side and sell-side analysts rated the listed companies within the scope of their research according to several criteria used in evaluating performance in corporate governance.
Category / Award Core Asia Results: Best CEO – Mr. Eddy Tang Best CFO – Mr. Levin Lee Best IR Team Best IR Program Best ESG Best Board of Directors
Asia ex-Mainland China: The Most Honoured Company Best CEO – Mr. Eddy Tang Best CFO – Mr. Levin Lee Best IR Team Best IR Program Best ESG Best Board of Directors Best Investor Relations Professional – Ms. Hermione He / Ms. Ronnie Hou
Asia Small and Midcap: The Most Honoured Company Best CEO – Mr. Eddy Tang Best CFO – Mr. Levin Lee Best IR Team Best IR Program Best ESG Best Board of Directors Best Investor Relations Professional – Ms. Hermione He
Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, “The Group is honored and grateful to receive these awards. We will continue to spare effort with the aim of further consolidating the leading position in the healthcare market and maximizing our shareholder value. The Group wishes to excel together with our much-valued stakeholders and stay proactive in continuously refining our strategies for the overall welfare of our company and the greater community.”
About EC Healthcare EC Healthcare is Hong Kong’s largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group’s high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.
The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center EC EYE and EC Veterinary Hospital and Imaging Center.
*According to independent research conducted by Frost and Sullivan in terms of revenue in 2021 and 2022
For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Tim Tin Tel: (852) 2136 6952 / 2169 0467 / 3920 7654 Fax: (852) 3170 6606 Email: ech@iprogilvy.com
Earlier this year, Tammy Phan, CEO and Founder of Luxe Du Jour, was recognized by SME Canadian Business Association Awards; Luxe Du Jour won Business of the Year. The Company hasn’t slowed down since constantly innovating and solving market problems. Luxe Du Jour is the newest go-to destination to connect handbag renters and lenders – think of it as the “Airbnb” of bags. It is an innovative way where you can become a borrower and rent out high-end authentic designer handbags or you can be a lender and make passive income off the bags you do not currently use and would like to lend out through their company. Luxe Du Jour only accepts the following brands; Chanel, Louis Vuitton, Dior, Hermès, Céline, Givenchy, Prada, Gucci, Saint Laurent, Fendi, Cartier, Van Cleef & Arpels, Chloé, Balenciaga, Valentino, and Goyard.
Tammy Phan (CEO and Founder) stated: “Luxe Du Jour started in 2016 with the intent of bringing sustainability to the luxury market. The founder put together their collection of handbags and started selling them on consignment!”
Luxe Du Jour is a luxury consignment company that offers a wide selection of pre-loved, professionally authenticated designer handbags. The company also operates Luxe Bag Rental, where luxury authentic handbags can be rented for 15 or 30 days, and Luxe Bag Spa, which restores pre-loved bags.
Luxe Du Jour is planning an expansion of a US head office. Luxe Du Jour currently ships worldwide and has 5 head offices internationally. Phan is continuing to expand the business and turn it into a fintech company with the launch of her App coming later this year. “Luxe Du Jour is the brand to watch with all their innovation coming out this year,” says CEO Tammy Phan.
Luxe Du Jour Shantal Zoto +1-833-746-7589 luxedujour.ca
SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, is pleased to announce that, the Company has received HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation (“HKSTP”), which is the highest subsidy amount in the Clinical Translational Catalyst (CTC) program of HKSTP.
CTC program is offered by HKSTP Institute for Translational Research (ITR), the overarching aim is to provide a platform to transform Hong Kong and Greater Bay Area to become the go-to destination for translational medicine in the region. Under this program, funding support will be provided to biomedical companies of HKSTP to bring innovative, life-changing therapies and technologies to patients.
SinoMab stood out from many biopharmaceutical companies in the CTC program and was granted the highest subsidy amount, embodying the recognition by the evaluation committee on the Company’s product candidates and research and development (R&D) plan. According to the agreement signed by both parties, HKSTP will provide SinoMab a subsidy of HK$8 million in the next 42 months in phases according to its clinical plan and progress for the clinical study of SN1011, the Company’s key product, for the treatment of multiple sclerosis (MS).
SN1011 is SinoMab’s key product and third-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor. Following the approval of Investigational New Drug (IND) applications of SN1011 for systemic lupus erythematosus (SLE) and pemphigus vulgaris (PV) by the National Medical Products Administration (NMPA) on 27 August 2020 and 23 June 2021, respectively, the IND application of SN1011 for MS has been approved by the NMPA on 19 April 2022. The Company plans to initiate Phase II clinical study to evaluate the efficacy and safety of SN1011 in patients with MS in China and expects to enroll the first patient in the fourth quarter of 2022. The IND application of SN1011 for neuromyelitis optica spectrum disorder (NMOSD) was also accepted by the Center for Drug Evaluation (CDE) of the NMPA on 6 June 2022.
Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: “By launching the CTC program, HKSTP provides great support to local biopharmaceutical companies on their New Drug R&D. As a biopharmaceutical company raised in Hong Kong for 20 years, we are grateful for the long-term support and assistance of the HKSTP in promoting innovation and development of local biopharmaceutical companies. Previously, President Xi Jinping, and the Chief Executive of the HKSAR, Mr. Lee Ka-chiu, visited the Science Park, with the desire to forge Hong Kong into an international Innovation and Technology hub, demonstrating the country’s high appreciation of Hong Kong innovative technology development. We are excited by the unprecedented opportunities. With the smooth progress of clinical trials of the Company’s key candidates, the subsidy from the HKSTP will provide a solid foundation for the Company’s continuous R&D and stepping toward commercialization. We will fully grasp the opportunity to accelerate the R&D and clinical trials of various products, further expand the product pipeline and potential indications, speed up the realization of product commercialization, adhere to the concept of independent innovation, strive for the well-being of patients and create value for shareholders.”
About Hong Kong Science and Technology Parks Corporation Established in 2001, HKSTP attracts and nurtures talent, accelerates and commercializes innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Its growing innovation ecosystem is built around its key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realizing a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of the industry.
Through its infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
About SinoMab BioScience Limited SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for RA in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin’s lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.
EC Healthcare (the “Company”, which together with its subsidiaries is referred to as the “Group”, SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the excellent result in the “All-Asia Executive Team Rankings 2022” under the category of Healthcare & Pharmaceutical organized by Institutional Investor, an international magazine. The Group is delighted recognize as The Most Honoured Company (Healthcare & Pharmaceutical) in the division – Asia (excluding mainland China), which represents recognition of the Group’s impressive performance by the investors and the market.
Recognized as an authoritative ranking by industries, “All-Asia Executive Team Rankings” celebrates the outstanding companies and management teams in Asia. Buy-side and sell-side analysts rated the listed companies within the scope of their research according to several criteria used in evaluating performance in corporate governance.
Category / Award Core Asia Results / Best IR Team
Asia ex-Mainland China: The Most Honoured Company Best CEO – Mr. Eddy Tang Best CFO – Mr. Levin Lee Best Investor Relations Program Best ESG Best Investor Relations Professional – Mr. Christopher Wong / Ms. Hermione He
Asia Small and Midcap: Best CEO – Mr. Eddy Tang Best CFO – Mr. Levin Lee Best Investor Relations Program Best ESG Best Investor Relations Professional – Mr. Christopher Wong
Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, “The Group is honoured and grateful to receive these awards. We will continue to spare tremendous effort with the aim of further consolidating the leading position in the healthcare market and maximizing our shareholder value. The Group wishes to excel together with our much-valued stakeholders and stay proactive in continuously refining our strategies for the overall welfare of our company and the greater community.”
About EC Healthcare EC Healthcare is Hong Kong’s largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group’s high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.
The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, a advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.
*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021
Contact